The mammalian target of rapamycin (mTOR) kinase is implicated in the regulation of initiation of mRNA translation, cell cycle progression, and cellular proliferation. The mTORC1 pathway is commonly activated in acute myeloid leukemia (AML) and represents a major target for AML therapy. However, the efficacy of allosteric mTORC1 inhibition with rapamycin and its analogs is limited in AML. The understanding of the mechanisms leading to rapamycin-resistance led to the development of second generation of mTOR inhibitors which directly suppress the mTOR catalytic activity in both mTORC1 and mTORC2 complexes. We therefore tested the dual PI3K/mTORC1/2 ATP-competitive inhibitor NVP-BEZ235 in AML. Interestingly, this compound has a strong anti-leukemic activity by overcoming mechanisms leading to rapamycin-resistance. 
INTRODUCTION
In acute myeloid leukemia (AML), the constitutive activation of signal transduction pathways enhances the survival and proliferation of the leukemic cells (1) . The increased understanding of AML biology in recent years however contrasts with the remaining poor prognosis for patients with this disease (2) . The development of new therapies is thus highly desirable and the targeting of signalling pathways that are preferentially activated in transformed AML cells represents a rapidly expanding research field in this regard (1) .
The class IA Phosphoinositide 3-Kinase (PI3K) is a lipid kinase that is mainly induced following growth factor receptor activation. Upon PI3K stimulation, the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) induces the activating phosphorylation by PDK1 of the oncogenic kinase Akt on T 308 . The PI3K signalling pathway is frequently deregulated in cancer cells and its constitutive activity strongly contributes to the oncogenic process (3) . In AML, constitutive PI3K/Akt activation, mainly due to the activity of the PI3K p110δ isoform (4, 5) , is detected in 50% to 80% of samples at diagnosis (6) (7) (8) and has recently been linked to an IGF-1/IGF-1R autocrine loop (9) . Although specific inhibition of PI3K p110δ activity barely induces apoptosis in AML (9, 10) , the PI3K/Akt pathway markedly contributes to AML cell proliferation (4, 5, 9) , therefore representing a potential therapeutic target for this disease.
The serine/threonine kinase mTOR (mammalian target of rapamycin) is a component of two exclusive complexes, mTORC1 and mTORC2, which are defined by both their molecular composition and substrate specificity. The interaction of mTOR with raptor (regulatory associated protein of mTOR) defines mTORC1, whose substrates include the ribosomal protein S6 Kinase (S6K) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BPs) (11, 12) . The mTORC1 pathway generally controls the cap-dependent translation of mRNAs through the phosphorylation of the key translation regulator 4E-BP1
WESTERN BLOT
Whole cell extracts and western blots were performed as previously described (25) using antibodies listed in Supplemental Table 1 . The images were captured using a CCD camera (LAS3000 from FujiFilm). The signal intensity was quantified using Multigauge software from Fujifilm®
FLOW CYTOMETRY
Apoptosis was quantified by annexinV-PE staining (Becton Dickinson, Le Pont-De-Claix, France) as previously described (34) and cell cycle was assessed using DNA staining with 
RESULTS

NVP-BEZ235 inhibits PI3K and mTORC1 signalling in AML cells.
The dual PI3K/mTOR inhibitory activity of NVP-BEZ235 was assessed both in human AML cell lines (MV4-11, MOLM-14 and OCI-AML3) and in primary leukemic cells sampled from AML patients at diagnosis. Dose-dependent experiments (from 1 to 1000nM)
revealed that PI3K activity is strongly inhibited by NVP-BEZ235 treatment in all three AML cell lines tested. Indeed, Akt phosphorylation on T 308 , which directly reflects the inhibition of PI3K activity, was suppressed by a 10nM dose of NVP-BEZ235 (Fig. 1A) . Moreover, NVP-BEZ235 was found to inhibit P70S6K T 389 phosphorylation from 25nM in a similar manner to 10nM rapamycin, reflecting an inhibition of mTORC1 activity (Fig. 1A) . In these experiments, the broad-spectrum kinase inhibitor LY294002 was used as a control for the inhibition of Akt T 308 and P70S6K T 389 phosphorylation (Fig. 1A) (Fig. 1A) . These results emphasize the specificity of NVP-BEZ235 against class IA PI3K and mTOR activities in AML cells. Based on these results, all subsequent experiments were performed using 10, 100
and 1000nM concentrations of NVP-BEZ235.
In a cohort of 10 primary AML samples, treatment with NVP-BEZ235 was also found to induce a dose-dependent decrease in Akt T 308 and P70S6K T 389 phosphorylation without affecting the ERK/MAPK pathway (Fig. 1B , left panel and Supplementary Fig. S1 ).
Quantification by western blotting of these 10 AML samples (Fig. 1B right S2 ). NVP-BEZ235 thus behaves as a potent cell-permeable PI3K and mTORC1 inhibitor in leukemic cells.
NVP-BEZ235 inhibits mTORC2 activity in AML cells.
We further wished to examine mTORC2 activity in AML cells. We first assessed the mTOR autophosphorylation site on S 2481 (35, 36) , as this closely reflects its catalytic activity in both mTORC1 and mTORC2 complexes (29) . Interestingly, we found that in the AML cell lines, NVP-BEZ235 induced a dose-dependent inhibition of mTOR S 2481 phosphorylation, in contrast to rapamycin, ( Fig. 2A ) which suggested that not only mTORC1 but also mTORC2 could be targeted by this compound. The Akt and SGK serine/threonine kinases are the best characterized mTORC2 substrates (27, 29, 37) . As expected, NVP-BEZ235 suppressed Akt S 473 phosphorylation in a dose-dependent manner ( Fig. 2A) . In addition, the phosphorylation of FOXO3a at S 253 , which directly reflects the activation state of Akt on S
473
, was also inhibited to a similar extent by NVP-BEZ235 ( Fig. 2A) . The activity of SGK was then assessed by testing the phosphorylation of its substrate NDRG1 on T 346 (38) . Accordingly, NVP-BEZ235 strongly inhibited NDRG1 T 346 phosphorylation ( Fig. 2A) It has been established that full Akt and SGK activation also requires PI3K activity (39) (40) (41) and to therefore more precisely assess the biochemical activity of the mTORC2 complex in AML cells, we tested the phosphorylation status of paxillin on Y 118 , reported as an indirect substrate for mTORC2 activity in non-transformed cells (17) . We verified that this phosphorylation was indeed dependent on mTORC2 activity in primary AML cells by disrupting the mTORC2 complex using rictor siRNA. As shown in Figure 2C 
NVP-BEZ235 inhibits cap-dependent mRNA translation and oncogenic protein synthesis in AML cells.
The phosphorylation of 4E-BP1 is the limiting step in the assembly of the translation initiating complex eIF4F, and is initiated by the interaction between the eIF4E and eIF4G
proteins (25) . We thus performed 7 mGTP pulldown assays using the MV4-11 cell line to examine whether a 24 hour exposure to NVP-BEZ235 modulates the interaction between eIF4E and eIF4G (active translation) or 4E-BP1 (inactive translation). As shown in Figure 4A , NVP-BEZ235 decreased the levels of eIF4G but increased the amounts of 4E-BP1 associated with eIF4E, indicating an inhibition of eIF4F assembly.
We additionally performed polysome analysis in MV4-11 cells from which we extracted a non-polysomal fraction corresponding to ribosomes not engaged in translation and a polysomal fraction containing the ribosomes undergoing active translation (25) . After centrifugation through a sucrose gradient, continuous measurements at a 254 nm optical density revealed three peaks corresponding to 40S and 60S ribosome subunits and 80S
Research.
on November 
NVP-BEZ235 inhibits the proliferation of AML cells
We investigated the anti-leukemic activity of the NVP-BEZ235 compound and assayed the cell proliferation rates using [ 3 H]-thymidine pulse assays. We consistently observed a dose-dependent decrease in cell proliferation, with an IC 50 of 59nM in primary AML cells (n=4), and of 25nM in MV4-11, 45nM in MOLM-14 and 60nM in OCI-AML3 cells (Fig. 5A ).
Consistent with its anti-proliferative effects, the cell cycle analysis using PI staining (Fig. 5C ).
NVP-BEZ235 inhibits the clonogenic growth of AML progenitors without affecting normal hematopoiesis.
We generated clonogenic cultures of primary AML cells and incubated these with 10 to 1000nM NVP-BEZ235. The subsequent levels of clonogenic leukemic colony formation (CFU-L) from three different AML samples were dramatically reduced with a mean decrease from 69% to 96% upon treatment with 10 to 1000nM NVP-BEZ235, respectively (Fig. 6A ).
In contrast, NVP-BEZ235 barely affected the clonogenic growth and differentiation of normal CD34+ hematopoietic progenitors, even at the maximal concentration of 1000nM. The number of mixed (CFU-GEMM), erythroid (BFU-E) or granulo-monocytic (CFU-GM) colonies was not significantly decreased by NVP-BEZ235 (Fig. 6A ).
NVP-BEZ235 induces apoptosis in AML cells but not in normal CD34+ cells.
We next determined the impact of NVP-BEZ235 upon AML cell survival. The NVP-BEZ235 was found to induce from a 100nM dose a significant apoptosis response in primary AML samples and in MV4-11 cells, as evidenced by an increase in annexin V staining ( (27) . This suggests that mTORC2
inhibition plays a role in the anti-leukemic activity of these molecules (27) . We thus speculate that the targeting of mTORC2 may contribute to the anti-leukemic activity of NVP-BEZ235.
The critical mechanism underlying NVP-BEZ235 action, however, may also result from the inhibition of protein translation. We recently emphasized that the weak antileukemic activity of the rapalogs was mainly due to the sustained high level of 4E-BP1 phosphorylation in AML cells treated with these compounds (25) . Conversely, we show herein that in contrast to rapamycin, NVP-BEZ235 strongly blocks mTOR catalytic activity.
This results in the inhibition of 4E-BP1 T 37/46 phosphorylation, residues which have been reported to be direct substrates for mTOR catalytic activity (49). As 4E-BP1 phosphorylation follows a hierarchical process in which the priming phosphorylation on T 37/46 residues is rate limiting (16, 50) , the inhibition of mTOR catalytic activity results in a complete inhibition of Phospho-4E-BP1 S 65 was quantified and normalized to actin signal intensity in 14 AML samples. Results are expressed as a ratio to the control incubation without NVP-BEZ235.
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